Dainona Signs CDMO Agreement with Samsung Biologics for Development of DNP-019 Antibody
[Asia Economy Reporter Yoo Hyun-seok] DinoNA, which is preparing to merge with Kumho HT, announced on the 1st that it has signed a contract for contract development and manufacturing organization (CDMO) services with Samsung Biologics for the fast-track development of the COVID-19 therapeutic antibody ‘DNP-019’.
COVID-19 neutralizing antibody treatments require administration in large quantities to patients, so high productivity is essential for the successful development of these therapeutics.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Bull Market End Signal? Securities Firm Warns: "Sell SK hynix 'At This Moment'"
- "Looks Even More Like Him in Person": Crowds Gather to See 'Trump Lookalike' Albino Buffalo
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
DinoNA selected the candidate substance considering productivity from the early stages of DNP-019 development and signed the contract with Samsung Biologics, which has experience in developing and producing high titers of antibodies at 7g/L and bispecific antibodies at 4g/L.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
